[Pathogenesis of hepatitis C virus infection]

Area of Science:

• Hepatology
• Virology
• Immunology

Context:

• Hepatitis C virus (HCV) is a primary global cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma.
• HCV infection frequently becomes chronic due to the virus's genetic variability, which allows it to evade host immune responses.
• HCV-related end-stage liver disease is a leading indication for liver transplantation in many regions.

Purpose:

• To review the current understanding of Hepatitis C virus (HCV) pathogenesis, treatment, and challenges.
• To highlight the impact of HCV on global liver disease and transplantation.
• To discuss the limitations in current research models and the future directions for HCV control.

Summary:

• HCV infection leads to significant liver damage primarily through immune-mediated mechanisms, not direct viral cytopathy.
• Combination therapy with alpha interferon and ribavirin achieves sustained virological response in approximately 40% of patients.
• Pegylated interferon has improved treatment efficacy, but challenges persist in understanding co-factors and developing effective vaccines due to viral protein variability.

Impact:

• Advances in understanding HCV pathogenesis and treatment have been made, but significant challenges remain.
• The development of therapeutic vaccines is considered more feasible than prophylactic vaccines due to HCV's genetic diversity.
• Continued research efforts are crucial to control HCV-related diseases and reduce the global burden of liver disease.